Skip to Content

Join the 'Insulin Glargine / lixisenatide' group to help and get support from people like you.

Insulin Glargine / lixisenatide News

Dealing With Diabetes Distress

Posted 5 days ago by Drugs.com

THURSDAY, Feb. 16, 2017 – People with diabetes have to think about their condition and make treatment decisions constantly – and all that extra work and worry can lead to psychological distress at times. "Diabetes distress" isn't the same as depression, however, diabetes experts note. It's a condition unique to the 24/7 demands that come with diabetes, particularly for people dependent on insulin. "The day you develop diabetes, it's like the universe just handed you a new full-time job that you have to do in addition to whatever else you're doing. It's a special job that has a big impact on the rest of your life. There's no pay and no vacation," said William Polonsky, president of the Behavioral Diabetes Institute in San Diego. Alicia McAuliffe-Fogarty, vice president of lifestyle management at the American Diabetes Association, put it this way: "Diabetes distress is the extra burden ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Lantus, Diabetes, Type 1, Glucophage, Novolog, Glipizide, Humalog, Insulin Resistance, Janumet, Glyburide, Lantus Solostar, Invokana, Levemir, Actos, Pre-Diabetes, Glimepiride, Novolin R, Amaryl

Sanofi Receives FDA Approval of Soliqua 100/33 (insulin glargine and lixisenatide) for the Treatment of Adults with Type 2 Diabetes

Posted 22 Nov 2016 by Drugs.com

PARIS, Nov. 21, 2016 /PRNewswire-USNewswire/ – Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved once-daily Soliqua 100/33 (insulin glargine & lixisenatide injection) 100 Units/mL & 33 mcg/mL for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin (less than 60 Units daily) or lixisenatide*. Soliqua 100/33 is the combination of Lantus (insulin glargine 100 Units/mL) and lixisenatide, a GLP-1 receptor agonist, in a once-daily injection, studied in a Phase 3 program of more than 1,900 patients. In an insulin intensification study, Soliqua 100/33 showed better HbA1c (average blood sugar over time) lowering versus Lantus with a majority of the 736 patients (55% vs. 30%) achieving the American Diabetes Association target of less than 7% at 30 weeks. Patients treated with Soliqua 100/33 experienced similar rates of documented ... Read more

Related support groups: Diabetes, Type 2, Lantus, Insulin Glargine, Soliqua, Adlyxin, Lixisenatide, Insulin Glargine/lixisenatide

Ask a Question

Further Information

Related Condition Support Groups

Diabetes, Type 2

Related Drug Support Groups

Soliqua

Insulin Glargine / lixisenatide Patient Information at Drugs.com